Acute leukimia is not a common disease, but in the past quarter of a century it has acquired an interest, both to the medical profession and to the public, which is out of proportion to its frequency. The emotions of the general public have been stirred by stories in the newspapers of children and young people suddenly struck down as by one of Jove's thunderbolts. To us it is of interest because it was one of the first malignant diseases which showed any therapeutic response to chemotherapy, and because it offers unique opportunities for studying the effects of chemical agents on the cancer cell.
Therapeutics today regards itself as a science, but it is as well to recall that its whole structure is founded upon the naive and unscientific assumption that all disease is curable. So much energy and so much money have been expended in the search for a cure for acute leukaemia that it is wise to ask ourselves whether we have any reason for supposing that this malady can indeed be cured. Perhaps we are no more than the haematological counterparts of King Canute's courtiers, commanding the waves to recede while the leukeemic tides rise higher and higher round the royal ankles.
The stimulus which encourages so many earnest workers to continue the search is undoubtedly the astonishing phenomenon of the 'complete remission' which treatment may induce. Clinical hematology holds no more dramatic experience than that of seeing a patient presenting one day all the most sinister signs of the most malign of all blood diseases, and a week or two later in apparently irreproachable health with normal peripheral blood and bone marrow. It is difficult to believe that a change so complete cannot somehow be rendered permanent. Hitherto, however, it has been the almost universal experience that within weeks or months evidence of leukamia reappears, and the disease resumes its ineluctable progress. I say 'almost universal', because records have now been collected of more than 130 patients who have survived five years or longer since a diagnosis of acute leukemia was established (Burchenal 1966) . In all the diagnosis was indisputable, and at least 11 are alive without evidence of leuktmia more than ten years after it was made. In most forms of malignant disease survival for such a period is equated with cure. All these patients had received treatment, but for the purposes of this argument it is irrelevant whether the remission was therapeutic or spontaneous. The possibility, however remote, that it may endure for more than ten years is enough.
Complete spontaneous remissions, although rare, have long been recognized. Figures for their incidence date back to the days before chemotherapy, and range from 4 % to 10 % with a mean duration of ten weeks (Diamond & Luhby 1951 , Southam et al. 1951 . It is improbable that any of the examples of recovery from acute leukaemia reported in the past would be diagnostically acceptable today (Forkner 1938) . Some hope may perhaps be drawn, too, from the reports of spontaneous recovery from chronic lymphatic leukxmia, which have appeared from time to time and of which some undoubtedly are indisputable (Durant & Finkbeiner 1964) . I have certainly seen one such case. Nevertheless, it may be unjustifiable to draw parallels between this disease and the acute variant. In summary, we must admit that while we have no conclusive evidence that acute leukaemia is curable, a sufficient number of patients have survived long enough to justify the word 'recovery'. Such long survival was unknown before the introduction of chemotherapy. Even these few instances should encourage workers in this field.
The aim of treatment in acute leuktmia can be stated as the obliteration of all leukemic cells in the body. There seems good reason to suppose that the nearer this destruction approaches the absolute, the greater the chance of complete and prolonged remission. It is assumed that if even one leuktemic cell remains viable, it will divide and in time lead to recurrence. It has been calculated that in the average 6-year-old child with acute lymphoblastic leukvmia there are 1 x 1012 leukeemic cells. It needs 41 divisions for the progeny of a single cell to reach this number. If a constant generation time of 4-6 days is assumed, it would take 164 to 246 days for a single leukemic cell to produce a complete relapse (Frei & Freireich 1965 ). These interesting, if visionary, mathematics can clearly be challenged on several grounds, but if they are accepted a patient well after 246 days of remission without maintenance treatment should no longer be in danger of relapse.
At present the usual sequence in a patient responding to treatment is clinical and hematological remission, followed after a matter of weeks or months by reappearance of signs of the disease. We speak of this as 'relapse', but it may mean either that a few leukaemic cells did survive and that their multiplication has led to a reappearance of the leuktemia, or that all were eradicated but that a persisting leukaemogenic agent has evoked for the second time a leukaemic process. We should speak, therefore, either of inadequate treatment or of a second attack.
It may well be that leuktemia cannot be cured simply by obliterating the entire leukemic clone or clones of cells, although such evidence as we possess favours the notion. We are, indeed, bound to make this assumption for we know so little about leukemogenesis, and the agents we recognize, such as ionizing irradiation, presumably do not exert an effect after their application has ceased. I am not aiming here at a comprehensive review of the treatment of leukemia. I have no experience of immunological methods or of marrow transplantation, and will therefore say little on these subjects. In the main I shall devote myself to a consideration of chemotherapy, what can be expected of it and current views on the most effective way in which the drugs at our disposal can be used. It is just twenty years since Farber (Farber et al. 1948 ) showed that folic acid antagonists could induce remission in the acute leukaemia of childhood. The background to this observation is of interest. The synthesis of folic acid was greeted with such acclaim that the drug was soon being prescribed in all disorders for which no rational treatment existed. Farber noted, in acute leuktemia, not only that there was no improvement but that folic acid actually fanned the flames of the leukeemic process. He argued that induction of folic acid deficiency by the use of an antimetabolite should have the reverse effect.
The history of antileuktmic chemotherapy in the past two decades has been one of a succession of new drugs, often heralded by extravagant claims and by uncritical accounts of their efficacy in the lay press. While many have been discarded as ineffective or unduly toxic, the value of others and the most effective methods of using them have gradually become apparent. It is possible now to draw up a short list of the agents which have gained an established position, and in chronological order of their introduction they are: the folic acid antagonists of which methotrexate is that in general use; the corticosteroids, mercaptopurine, cyclophosphamide, methylglyoxal bisguanylhydrazone (methyl GAG), vincristine, cytosine arabinoside (ara-C) and rubidomycin.
Methotrexate, formerly known as amethopterin, is the only folic acid antagonist in common use. It may be given orally or by intramuscular or intravenous injection. Its common toxic effects are familiar to all, but an unusual type of hepatitis with fibrosis has recently been described (Colebatch 1966) .
Corticosteroids are usually given by mouth as prednisone or prednisolone; there is no advantage in exceeding a dose of 40-60 mg daily in an adult. The only clear conclusion which emerged from the first report of the MRC Working Party on the Evaluation of Different Methods of Therapy in Leuktmia (Medical Research Council 1963) , was that a high dose of corticosteroid (250 mg daily) notably reduced the length of survival.
Mercaptopurine is a purine antagonist and is given by mouth. It is well tolerated but excessive dosage will cause marrow aplasia.
Cyclophosphamide is a nitrogen mustard which is only activated in vivo. It can be given by mouth or intravenously. Its toxic effects are those of all nitrogen mustards, with the addition of alopecia and hemorrhagic cystitis.
Methylglyoxal bisguanylhydrazone (methyl GAG), has been used little or not at all in this country. It is given by slow intravenous infusion. Its side-effects, which include mucosal ulceration, thrombophlebitis, diarrhoea, desquamation of the feet and bone-marrow aplasia are so severe that it is said to have little practical use (Levin et al. 1965) . It is a drug of which I have no experience.
Vincristine sulphate is one of a number of alkaloids derived from the West Indian periwinkle Vinca rosea. It is given by intravenous injection. Alopecia is the rule; leukopenia, 1Section ofMedicine neuropathy and constipation occur but it is seldom troublesome when doses are given at weekly intervals.
Cytosine arabinoside (ara-C) again has been little used in this country, and I have had no experience of it. It is given by slow intravenous infusion. It appears to be well tolerated.
Rubidomycin, which appears to be identical with daunomycin, is an antibiotic isolated from cultures of Streptomyces ceruleorubidus. It is given intramuscularly. It produces with great rapidity a profound aplasia of the bone marrow. Some patients show signs of myocardial damage with tachycardia and hypotension. Epilation is the rule, but the hair grows again, and mucosal ulceration is common during the aplastic phase.
Before discussing the detailed use of these drugs, there are some general points which demand mention. Perhaps first I should define the term 'complete remission'. The leukemic patient is said to be in complete remission when the usual methods of investigation disclose no evidence of leukemia. This implies no abnormalities on physical examination. Peripheral blood with a hemoglobin level above 14g/100 ml, a leucocyte count between 4,000 and 10,000/mm3, of which 1,600 or more are segmented neutrophils, a platelet count above 200,000/mm3 and a cellular bone marrow with fewer than 5 % of blasts, less than 15 % of lymphocytes and monocytes and a normal proportion of megakaryocytes, or about 6 per 10,000 nucleated cells.
Mathe (Mathe, Mery, Cattan, Schneider, Amiel, Schlumberger, Poisson & Wajcner 1966) has'recently shown that these criteria are inadequate, and that if multiple bone marrow punctures and testicular, hepatic and renal biopsies are made, and leucocyte concentrates and a specimen of cerebrospinal fluid examined, evidence of residual leukxmic foci is often obtained when the conventional requirements of complete remission are satisfied. Here I use the term 'complete remission' in the older sense. I doubt whether the British patient with acute leukemia has the fortitude his French counterpart must possess, to accept such an investigative onslaught. Nevertheless, Mathe's observations are of great value, for they explain many therapeutic failures.
There are certain factors which influence the response to treatment of the patient with acute leukmemia, irrespective of the drugs used. The two most important are age and the cytological type of leuktmic process. Since Hayhoe et al. (1964) showed 'that there were probably two chief varieties of hemopoietic stem cell, it has become usual to place the acute leukwemias in one of two cytological categories, lymphoblastic and others. The second is mainly composed of the myeloblastic variety, with some instances of myelomonocytic leukemia (Naegeli type), some of acute erythrmemia or erythromyelosis (Di Guglielmo's syndromes) and an occasional example of histiocytic leukwmia (Schilling type). This second group will be referred to as 'myeloid' for reasons of brevity. The separation into these two broad divisions is undoubtedly justified by their difference in therapeutic response.
Remission is procured more readily in lymphoblastic leukemia than in myeloid. Although this greater readiness to remit is seen at all ages, it is more evident in children than in adults. Bernard's figures for 300 patients with acute leukTmia treated by a variety of methods are as follows (Bernard et al. 1962 with acute myeloid leukemia there was complete remission in only 7 %.
The frequency with which therapeutic remission can be obtained in the acute lymphoblastic leuk,emia of childhood has led to these patients being used as experimental models. I mean this in no derogatory way, but the tendency is for all new drugs and drug combinations to be tested in these children. Impressive results are often obtained. Optimistic reports are published and spirits rise. It is important to take a realistic view and remind oneself that adults with acute leukaemia far outnumber children, and that the myeloid variety is overall far commoner than the lymphoblastic.
Two other factors influence the therapeutic response in acute leukxmia. The first is sex. Bernard's figures (Bernard et al. 1962) show that in lymphoblastic leukaemia complete remissions were obtained in 72 % of 80 females but in only 54% of 100 males. In acute myeloid leuktmia, the figures for complete remission were 17-0 % in 51 females, and 6-5 % in 61 males. It is of interest that in both Hodgkin's disease and chronic myeloid leukwmia, the course in women is also more favourable than in men.
The second factor is the initial leucocyte count. Bernard showed this to be without influence until the figure of 100,000/mm3 was reached, when the frequency of remission was abruptly halved. The MRC Working Party (Medical Research Council 1963) found that a blast count of more than 25,000/mm3 was associated with early death.
There is no need to state that the drugs I have mentioned have little specificity of action, for this is a shortcoming of all the chemotherapeutic agents we possess. It is clearly true that they are more active against some types of hmemopoietic cell than others, for they induce remission far more readily in lymphoblastic than in acute myeloid leukmmia. In general, however, their destructive effects upon leukwmic cells are accompanied by a similar action upon other haemopoietic elements. The majority of patients, therefore, have to survive an episode of bonemarrow aplasia or at best of hypoplasia, and in favourable cases this is followed by regeneration of healthy bone marrow.
During this aplastic phase the patient is in jeopardy as a result of anamia, thrombocytopenia and neutropenia while the treatment, too, will certainly have greatly depressed his humeral immunity mechanisms. The gravity of this situation has been much increased recently with the introduction of more powerful drugs such as rubidomycin and with the use of higher doses. Anaemia is easily remedied by blood transfusion. There is good evidence that transfusion of platelets can control the haemorrhagic state due to thrombocytopenia (Alvarado et al. 1965 , Stutzman et al. 1966 ). Transfusion of leucocytes from patients with chronic myeloid leukxmia has been used in some centres (Morse et al. 1961 ); Mathe (Schwarzenberg, Mathe, Schneider, Amiel, Cattan & Schlumberger 1966 , Schwarzenberg, Mathe, Amiel, Cattan, Schneider & Schlumberger 1966 claims that it has an immunological effect as well as supplying the granulocytes the patient lacks. He describes six complete remissions in 21 patients with acute leuk2emia resistant to chemotherapy, and believes the effect was probably due to the immunological reaction of the transfused leucocytes to the recipient's antigens, particularly to those of his leukemic cells.
There are practical difficulties in obtaining patients with untreated chronic myeloid leukxemia, and healthy donors are unsuitable. It is estimated that the transfusion of 1 x 1011 granulocytes per square metre is required to raise the recipient's granulocyte count by 1,000/mm3. This number amounts to all the circulating granulocytes in two healthy adults.
Another measure which has been much canvassed of late is the nursing of patients in a pathogen-free environment (Mathe & Forestier 1965 , Mathe, Schwarzenberg, Schneider, Amiel, Cattan, Schlumberger & Faisler 1966 . There are at present few centres which can afford the staff or money to undertake this refinement of treatment.
So far there is little evidence that results justify the additional cost, the difficulties under which ordinary medical and nursing duties are carried out and the psychological distress which the patient is reported to suffer. Patients in this con-dition are, of course, ready victims to infection often by organisms which are scarcely pathogenic in health. Nevertheless, it is common experience that the bacteria encountered are probably more often derived from the patient's own alimentary tract than from his external environment.
During this phase of bone marrow aplasia, a prophylactic antibiotic is commonly prescribed. In the presence of active and demonstrable infection, the appropriate antibacterial agent will of course be given. Where no positive indication exists, we have been in the habit of using a combination of chloramphenicol and erythromycin, but more recently we have preferred cephaloridine.
The most effective way to use the antileukemic drugs had to be learned from experience. When the folic acid antagonists first took the stage, they were given until signs of toxicity appeared, withdrawn until the patient recovered from their sideeffects and then resumed. Much the same methods were used at first with the steroids and mercaptopurine. From the observation that the disease soon became resistant to a drug to which it had first remitted, the development of orderly sequential treatment was an obvious step. It became the rule to start with steroids, change to mercaptopurine directly relapse threatened and, finally, to methotrexate when resistance to mercaptopurine became evident. If no remission occurred with the first drug, a change was made to the second and if this failed, to the third.
Five or six years ago it began to be appreciated that while some of the available antileukxemic agents were more potent in inducing remission, others were more effective in maintaining it. Using acute lymphoblastic leukemia of childhood as an experimental model, it could be shown that prednisone induced complete remission in 57 % and vincristine in 55 %, while the figures for methrotrexate, mercaptopurine and cyclophosphamide were respectively 21 %, 27% and 18% (Freireich & Frei 1964) . Analysis of the effect of different drugs in maintaining remission revealed the superiority of methotrexate and mercaptopurine. The median duration of complete therapeutic remission without maintenance treatment was 5-9 weeks; when maintenance treatment with prednisone and vincristine was given the figures were 9-12 and 8 weeks; but when methotrexate and mercaptopurine were used, they were respectively 28 and 33 weeks. Later observations showed that combinations of drugs would increase the percentage of remissions procured. For instance, if prednisone and vincristine were used together, the figure rose to 85%; with methotrexate and mercaptopurine added to these, it reached 94%.
From these data sprang the methods many of us have been using for some time, of attempting to induce remission with one drug or drug com-bination, and of maintenance with another. It has been claimed that alternating two drugs during the phase of maintenance postpones the development of resistance. There is no agreement on this point. Zuelzer (1964) has been its strongest protagonist, and his method was to induce remission with a steroid-mercaptopurine combination, and for maintenance treatment to alternate methotrexate with mercaptopurine for periods of three months each. Controlled observations, however, have shown no difference between the median duration of remission in patients given methotrexate and mercaptopurine together, and those in whom they are alternated (Frei & Taylor 1963) . The dose, the interval between doses and the route of administration influence the efficacy of maintenance treatment in a surprising manner. Methotrexate given as maintenance treatment in doses of 3 mg/M2 daily by mouth results in a median duration of 3-3 months. When given twice weekly by intramuscular injection in a dose of 30 mg/M2, the figure rises to 17 months (Acute Leukxmia Group B 1965) . Improvement has also been noted in adult acute myeloid leukaemia when mercaptopurine is given as maintenance treatment in doses of 1 g at intervals of 4-7 days, compared with the conventional daily dose of 2 5 mg/kg (Bean 1967) .
Recently views have again begun to change, partly perhaps because of the theoretical but none the less valid criticism that what we call relapse really indicates inadequate treatment or a second attack of leukaemia, and partly because of the observations of Skipper et al. (1964) His painstaking work on L1210 murine leukemia showed that the percentage of leuksemic cells killed by a given dose of a drug remained constant, irrespective of the total number of leukaemic cells present, and that there was more chance of complete cure if treatment were given over a short time than if it was protracted.
Various schedules of treatment were devised to test the hypothesis that drug combinations in massive dosage over a short period, without prolonged maintenance treatment, might 'cure' acute leukaemia. I have already pointed out that there is some theoretical reason for supposing that if a child remains in complete remission for more than 246 days without maintenance treatment, there may be a chance that the leuk2emia is cured. These schedules consist of combinations of vincristine, methotrexate, mercaptopurine, prednisone and cyclophosphamide in varying doses given at varying intervals. They have received such names as VAMP, BIKE and POMP. Full details are not yet available, but for VAMP and BIKE the median unmaintained remission rates were 150 and 166 days, and 3 patients of 23 treated were surviving in complete remission without maintenance for over 800, 1,000 and 1,000 days (Burchenal 1966) .
The most recent combination is of prednisone, vincristine and rubidomycin. With this Mathe (Mathe et al. 1967) has reported 100% of complete remission in 11 children with previously untreated acute lymphoblastic leukmemia, and 4 in 5 previously treated children. He proposes to follow this method of induction of remission with maintenance treatment which entails irradiation of the central nervous system to a dose of 1,000 rads, followed by successive monthly periods during the first of which methotrexate is given intravenously and intrathecally, during the second mercaptopurine and during the third cyclophosphamide. This is to be followed in its turn by active immunotherapy with BCG or by vaccination with pooled leukmmic lymphoblasts.
Almost everything I have said hitherto refers to the acute lymphoblastic leukwmia of childhood. The same cytological variety in the adult responds perhaps half as frequently, but otherwise behaves much in the same way. It is the acute myeloid leukwmia of adults which resists treatment so stubbornly but which accounts for some 70-80 % of all cases. The remission rate in general lies between 7 % and 13 %. There is little evidence yet that specific treatment prolongs survival (Dameshek et al. 1966) . The prospects of remission are so remote that it is in this variety perhaps that calculated risks may justifiably be taken. Methyl-GAG will, it is claimed, produce remission in some 25% : higher figures are given by its combination with other drugs, 33 % with mercaptopurine (Bernard, Boiron, Jacquillat, Najean & Seligman 1966) , and 42% with hydroxystilbamidine (Schwarzenberg, Schneider, Cattan, Amiel, Schlumberger & . There is no question that its toxic effects are profound, but only those who have used it can say whether they are sufficiently severe to make it unacceptable. A drug which does not share these disadvantages is cytosine arabinoside (Howard et al. 1966 ). This is reported as capable of inducing remission in 30 % of adults with acute myeloid leukemia (Bernard, Boiron, Jacquillat, Weil & Najean 1966) .
Perhaps the most promising recent addition to our armoury is rubidomycin. Bernard (Bernard et al. 1967 ) has used it in 21 cases of acute myeloid leukwmia and has obtained complete remission in 9. It is noteworthy that fatal marrow aplasia was recorded in 6. Our own results have been less good. We have obtained 2 complete remissions in 10 adults with acute myeloid leukaemia, but in 5 death was probably due to marrow aplasia. We have been much impressed by the brutal effect of this new agent on the bone marrow, and by the difficulties of managing the profound aplasia which results. It remains to decide which of this large number of therapeutic programmes we should select for our patients. The mass attack with high dosage of all the drugs known to be potent, as in the VAMP, BIKE and POMP schemes, has not yet established its superiority to gentler methods and does not offer cure. In acute lymphoblastic leukzemia, there is no doubt that induction with a vincristine-prednisone combination gives the best results, but in view of Mathe's report (Mathe et al. 1967) it may be advisable now to add rubidomycin. In acute myeloid leukeemia, the most effective drug for induction of remission is rubidomycin. It is difficult to manage but the outlook is so bleak that the risks must be accepted. It seems clear that maintenance treatment must continue for the present. There is a suggestion that alternation of methotrexate and mercaptopurine, each being given for one month, may be better than the two combined. It is certain that it is no less effective. Methotrexate should be given intramuscularly twice a week, and at the onset one or two intrathecal injections are advisable. Mercaptopurine should be given in doses of 1 g every 4-7 days for an adult of average size.
The problems of therapeutic failure have already been mentioned. They are two: the first concerns the patients in whom the disease is resistant to treatment from the onset, and the second, the reason for the almost inevitable reappearance of the leukxmic process after weeks or months of complete remission. The first at present seems insoluble, for it is no answer to say that our drugs are insufficiently specific. The second, as has been said, is more likely to be due to inadequate treatment. It is now well known that apparently complete remission may be associated with persistent leukemic infiltrations in the meninges, or less commonly, in the liver, testes, ovaries, kidneys and skin. Mathe's methods of assessing remission are aimed at uncovering these, and more effective means of eradicating such foci will have to be devised. I have limited my remarks to practical therapeutics and have therefore had no time in which to mention the most exciting development in the treatment of acute leukemia. This is the discovery that some strains of the disease and some solid tumours, are dependent upon asparagine which their cells, unlike normal cells, are unable to synthesize. This deficiency is due to the absence of the enzyme asparagine-synthetase. When the body pool of asparagine is destroyed by treatment with asparaginase, the cells lacking asparaginesynthetase die apparently as a result of the accumulation within them of aspartic acid. Already some encouraging results of treatment with I-asparaginase have been noted, but the most important aspect of this discovery is that for the first time a metabolic difference between healthy and malignant cells has been demonstrated.
I am conscious of many lacune in this brief review of therapeutic trends in acute leukaemia. The investigator may be gratified by an increase during the last twenty years in the median survival of children with acute lymphoblastic leukemia from five to fourteen months, but it is cold comfort to a child's parents. Nevertheless, I hope that the hitherto impenetrable gloom of this disease is now relieved by an occasional glimmer of light, and that we may pursue it with a reasonable confidence that we are not chasing a will-o'-thewisp.
